The US Food & Drug Administration (FDA) has granted approval toActavis Inc., the US subsidiary of Actavis Group, to market diltiazem hydrochloride extended-release capsules USP, in all available strengths: 120mg, 180mg, 240mg, 300mg, 360mg, and 420mg. The company has already been commenced the distribution of the product.
Tiazac, and its generic equivalents, had US sales of approximately $76.3 million for the 12 months ending December 31, 2011, according to IMS Health.